Source: Annual Congress 2006 - Hospital-acquired pneumonia: from inflammation to treatment
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Chacón, A. Tejada, J. Casalduero, F. Clau, T. Martín, F. de Pablo, S. Bello (Zaragoza, Spain). Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values. Eur Respir J 2006; 28: Suppl. 50, 4504

Member's Comments

No comment yet.

Related content which might interest you: Mortality in patients with ventilator-associated pneumonia (VAP) and severe sepsis is determined by the number of organ failures Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Ventilator-associated pneumonia (VAP): epidemiology, empirical treatment and outcome Source: Eur Respir J 2005; 26: Suppl. 49, 188s Year: 2005 Treatment failure of severe and ventilator-associated pneumonia Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Type of acute respiratory failure and development of ventilator-associated pneumonia (VAP) Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Predictive value of procalcitonin in ventilator-associated pneumonia Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 How to prevent ventilator-associated pneumonia Source: Annual Congress 2013 –PG3 Infections and critical patients: emerging problems and clinical strategies Year: 2013 Cost of treatment failure in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 195s Year: 2007 Challenges in the management of hospital-acquired pneumonia including ventilator-associated pneumonia Source: ERS Course 2018 - Respiratory Infections Year: 2018 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002 Evidence on measures for the prevention of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1193-1207 Year: 2007 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Biomarkers and severity in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Validation of pneumonia severity models for healthcare-associated pneumonia (HCAP) Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 MR-proANP and prognosis of ventilator-associated pneumonia Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Copeptin and prognosis of ventilator-associated pneumonia Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens Year: 2008